全球-生物制药行业-全球生物制药：Covid-19疫苗101和时间表

Global Biopharma Covid-19 Vaccines 101 and Timelines: “When will I get mine?” (Call Transcript) Pharmaceuticals & Biotechnology | Conference Call Given the rapid pace of Covid-19 vaccine developments, Evan Seigerman (Large Cap Biotechnology) and Dominic Lunn (EU Pharma) hosted a call to break down the complexity into simple, actionable insights. We review what’s happening at the FDA with regard to approval, who is prioritized, and answer the #1 question we get about vaccine availability: “When can I get mine?” We have appended the full transcript of the call below. Replay: (855) 859-2056 or (404) 537-3406 Conference ID: 9686319 16 December 2020 Equity Research Americas | United States DISCLOSURE APPENDIX AT THE BACK OF THIS REPORT CONTAINS IMPORTANT DISCLOSURES, ANALYST CERTIFICATIONS, LEGAL ENTITY DISCLOSURE AND THE STATUS OF NON-US ANALYSTS. US Disclosure: Credit Suisse does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Research Analysts Evan Seigerman 212 325 4463 evan.seigerman@credit-suisse.com Dominic Lunn 44 20 7883 0471 dominic.lunn@credit-suisse.com European Pharma Team 44 207 888 0304 creditsuisse.pharmateam@credit-suisse.com 16 December 2020 Global Biopharma 2 Operator: Ladies and gentlemen, thank you for standing by and welcome to the COVID-19 Vaccines 101 and Updates Conference Call. At this time, all participants' lines are in a listen only mode. After the speaker's presentation there will be a question-and-answer session. To ask a question during this session, you will need to press star one on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star zero. I would now like to turn the conference over to your speaker today, Evan Seigerman. Thank you. Please go ahead Sir. Evan Seigerman: Thank you, Shannon and thank you everyone for joining us today. We had a lot of news, positive news, in the COVID-19 vaccine space and I'm really honored to have my colleague, Dominic Lunn, from the European Pharma Team who is the firm’s de facto expert in COVID-19 vaccine, who has been doing a lot of work since the trials have begun. So what we're going to do today is, we are taking all the news that's happening and breaking it down to plain English. I know from a biotech analyst; you're used to hearing lots of scientific jargon. We're going to try to remove that and make it easy to understand: what's happening, when you can get a vaccine, vaccine supply, and how we think about the world getting back to normal and getting out of the pandemic. So there is a slide deck that we sent around but if you do not have the slide deck, please send me an email at evan.seigerman@credit-suisse.com and we'll get